Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the diagnosis, treatment, and management of atopic dermatitis in developing countries and identifies significant unmet medical needs, particularly in access to care and effective treatments; it reports no clinical results.

This review discusses the pathophysiology of sleep disturbance in children with atopic dermatitis and highlights the need for further research on management strategies, but provides no new clinical results.

This study found that type 2 immunity may play a role in the development of alopecia areata in patients with extrinsic atopic dermatitis, indicating different immunological states compared to non-atopic patients.

This report describes the case of a patient who developed alopecia areata within five weeks of starting treatment for atopic dermatitis with dupilumab.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

This review discusses the variety of skin disorders associated with atopic dermatitis, exploring their complex relationships and shared genetic and environmental factors, but reports no new clinical results.

This study found that selective deletion of Ctip2 in epidermal keratinocytes in adult mice leads to atopic dermatitis-like inflammation and suggests Ctip2 plays a crucial role in skin barrier maintenance and inflammatory regulation.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study found that patients with atopic dermatitis have a higher risk of developing keloid, suggesting it may be an independent risk factor for keloid formation.

This study found that individuals with AA have a higher incidence of atopic and autoimmune conditions, suggesting both Th1 and Th2 immune responses may play a role in its development.

This case report suggests potential effectiveness of dupilumab for alopecia areata, though hair regrowth may result from indirect effects on inflammation in atopic dermatitis.

This study observed that apremilast treatment improved skin lesions and reduced pruritus in patients with chronic, severe atopic dermatitis and one case of hand and foot dermatitis.

In this study, 16% of patients on dupilumab for atopic dermatitis experienced mild cutaneous adverse events, most commonly facial redness and psoriasis, leading to discontinuation in about 3% of cases.

In this study, IFN-γ-stimulated iPSC-derived mesenchymal stem cell extracellular vesicles improved atopic dermatitis in mice by reducing Th2 cytokine activity, suppressing inflammation, and restoring skin barrier function, as evidenced by decreased itching and inflammatory markers.

This study identified both known and additional potential adverse reactions to tralokinumab in real-world use for atopic dermatitis, highlighting the importance of monitoring adverse events, especially in the first month of treatment.

This study found that Israeli patients with alopecia areata had a higher prevalence of comorbid conditions, including food allergies and chronic spontaneous urticaria, compared to matched controls.

In this case report, a 28-year-old woman developed a rash on her face and neck after receiving a dupilumab injection for atopic dermatitis.

This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.

In this study, 62.1% of Korean patients with chronic dermatologic diseases reported using complementary and alternative medicine, though many were dissatisfied with the results.

This study found that Rumex japonicus extract may help reduce symptoms of atopic dermatitis by inhibiting inflammatory responses in both cell cultures and a mouse model.

This study found that Muse cells, when injected subcutaneously, alleviated symptoms of atopic dermatitis in mice, suggesting potential for treating inflammatory skin conditions.

Dupilumab can cause psoriasis in some patients.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

This study reports a case where a biologic medication used for atopic dermatitis unexpectedly also treated concurrent alopecia areata.

This review examines the role of skin microbes in enhancing the skin barrier and their involvement in skin diseases like atopic dermatitis, while also discussing current and future therapeutic strategies targeting the skin microbiome.

This study found that paeonol-loaded liposomal gels demonstrated antioxidant effects and relieved inflammation in AD-like mice, suggesting potential benefits for treating atopic dermatitis.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This study found that adherence to topical hydrocortisone in adults with atopic dermatitis was inconsistent and not significantly different across different medication vehicles, though disease severity improved markedly within 2 weeks.

In this study, consuming a healthy, plant-based diet was associated with reduced skin inflammation and improved overall skin health, while the potential benefits of probiotics, synbiotics, and postbiotics for skin inflammation and tissue regeneration require further investigation.

This report describes a rare case of alopecia areata-like psoriasis, associated with skin lesions, following the use of dupilumab in a patient with atopic dermatitis.